This content is from: Patents

A stranger’s guide to pharma IP collaboration during COVID-19

In-house counsel from Eli Lilly, Novartis and other companies set out how to protect IP in collaborations with third parties and competitors

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | One Week Trial